Hepatitis B trials in China

In China 103 Also abroad 191

103 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 1Enrolling by invitation
A Phase I Clinical Trial of CPU-YL01 Injection in Patients With Chronic Hepatitis B.
Where
Beijing, Nanjing, Zhengzhou
Age
18 years to 70 years
People
74
Run by
Jiangsu Chuangyuan Life Science and Technology Co., Ltd.
See details and how to joinNCT07918456
Phase 1Not yet taking people in China
Phase Ia/Ib Trial of SCTA02A Injection in Healthy Adults and Patients With Chronic Hepatitis B
Where
Beijing
Age
18 years to 65 years
People
60
Run by
Sinocelltech Ltd.
See details and how to joinNCT07903831
Phase 2Taking people
A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)
Where
Beijing, Chengdu, Guangzhou, Hangzhou, Shanghai, Shenzhen
Age
18 years to 60 years
People
250
Run by
Brii Biosciences Limited
See details and how to joinNCT06650852
Phase 1Not yet taking people in China
A Clinical Study of AHB-121 in Healthy Participants and Chronic Hepatitis B (CHB) Participants
Where
Shanghai
Age
18 years to 65 years
People
110
Run by
Ausper Biopharma Co., Ltd.
See details and how to joinNCT07884864
Phase 4Enrolling by invitation
TAF vs TDF During the Pregancy
Where
Guangzhou
Age
20 years to 40 years
People
210
Run by
The Third Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT07542951
Phase 2Taking people
Phase 2 Study of AHB-137 in HBeAg Negative Chronic Hepatitis B (CHB) Participants in Asia Pacific Region
Where
Hong Kong
Age
18 years to 65 years
People
84 worldwide
Run by
AusperBio Therapeutics Inc.
See details and how to joinNCT07370207
Phase 3Not yet taking people in China
Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Response
Where
Anyang, Baoji, Beijing, Changchun, Changsha, Changzhi, Chengdu, Chifeng, Chongqing, Dalian, Deyang, Foshan, Fuzhou, Guangzhou, Guiyang, Haikou, Hangzhou, Harbin, Hefei, Hengyang, Huaihua, Jinan, Jingzhou, Kunming, Langfang, Lanzhou, Liaocheng, Lishui, Liuzhou, Lüliang, Luoyang, Meishan, Mudanjiang, Nanchang, Nanjing, Ningbo, Puyang, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Ürümqi, Weifang, Wenzhou, Wuhu, Wuwei, Xiamen, Xi'an, Xi’an, Xining, Yuncheng, Zhengzhou, Zhuhai, Zunyi
Age
18 years to 65 years
People
930
Run by
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
See details and how to joinNCT07797231
No phaseTaking people
Impact of Functional Cure of Chronic Hepatitis B on Patient-Reported Outcomes (PROs)
Where
Guangzhou
Age
18 years to 65 years
People
400
Run by
Zhiliang Gao
See details and how to joinNCT07855029
Phase 2Taking people
A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (A)
Where
Chongqing
Age
18 years to 60 years
People
1,200
Run by
The Second Affiliated Hospital of Chongqing Medical University
See details and how to joinNCT07852091
Phase 2Taking people
A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (B)
Where
Chongqing
Age
18 years to 60 years
People
1,200
Run by
The Second Affiliated Hospital of Chongqing Medical University
See details and how to joinNCT07845058
Phase 2Taking people
A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (A)
Where
Chongqing
Age
18 years to 70 years
People
120
Run by
The Second Affiliated Hospital of Chongqing Medical University
See details and how to joinNCT05769816
Phase 1Not yet taking people in China
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of ACT500 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Complicated With Chronic Hepatitis B
Where
Beijing, Shanghai, Ürümqi, Xiamen
Age
18 years to 60 years
People
24
Run by
Xiamen Amoytop Biotech Co., Ltd.
See details and how to joinNCT07589400
No phaseNot yet taking people in China
Sequential PD-1 Antibody and Pegylated Interferon Therapy for Nucleos(t)Ide Analogue-suppressed Chronic Hepatitis B
Where
Jinan, Taiyuan, Xi'an, Xi’an
Age
18 years to 55 years
People
60
Run by
Beijing 302 Hospital
See details and how to joinNCT07809165
Phase 2Taking people
A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (B)
Where
Chongqing
Age
18 years to 70 years
People
120
Run by
The Second Affiliated Hospital of Chongqing Medical University
See details and how to joinNCT05771402
Phase 4Taking people
ASC22 Combined With Peg-IFNa in Achieving Functional Cure in Patients With Chronic Hepatitis B Virus Infection
Where
Chongqing
Age
18 years to 60 years
People
120
Run by
The Second Affiliated Hospital of Chongqing Medical University
See details and how to joinNCT07573943
No phaseTaking people
Safety and Efficacy of TAF to Prevent MTCT of HBV in Middle/Late Pregnancies With High HBV DNA Load
Where
Guangzhou
Age
20 years to 40 years
People
200
Run by
Xingfei Pan
See details and how to joinNCT05466071
Phase 1Taking people
A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BRII-5395 in Combination With Sintilimab and Bevacizumab in Advanced Hepatitis B Virus Related Hepatocellular Carcinoma
Where
Beijing
Age
18 years to 70 years
People
21
Run by
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07557251
No phaseNot yet taking people in China
HCC Risk Prediction Model Based on Multimodal Data in Chronic Hepatitis B
Where
Beijing
Age
18 years and over
People
2,000
Run by
Beijing Friendship Hospital
See details and how to joinNCT07780357
Phase 1/2Taking people
Study of LW231 in Participants With Chronic Hepatitis B
Where
Hangzhou
Age
18 years to 60 years
People
270
Run by
Shanghai Longwood Biopharmaceuticals Co., Ltd.
See details and how to joinNCT07179575
No phaseTaking people
Long-term Follow-up Study to Evaluate Participants With Chronic Hepatitis B (CHB) Previously Treated With AHB-137 Injection
Where
Beijing, Changchun, Changhou, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Kunming, Lanzhou, Liuzhou, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Taiyuan, Wuhan, Xiamen, Xi’an, Zhengzhou, Zhenjiang, Zunyi
Age
18 years and over
People
200
Run by
Ausper Biopharma Co., Ltd.
See details and how to joinNCT07146100
No phaseTaking people
Peg IFNα-2b Therapy for Unresectable Mid to Late Stage HBV-HCC
Where
Nanjing
Age
18 years and over
People
33
Run by
Jinling Hospital, China
See details and how to joinNCT07769827
Phase 1Taking people
A Phase I Clinical Trial to Evaluate HECN30227 Injection in Healthy Subjects and Subjects With Chronic Hepatitis B
Where
Hefei
Age
18 years to 65 years
People
78
Run by
Sunshine Lake Pharma Co., Ltd.
See details and how to joinNCT07771140
Phase 1Taking people
ACT201 Injection in Healthy Participants and Participants With Chronic Hepatitis B (CHB)
Where
Shanghai
Age
18 years to 65 years
People
72
Run by
Xiamen Amoytop Biotech Co., Ltd.
See details and how to joinNCT07741461
Phase 2Taking people
A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)
Where
Beijing, Changzhou, Chengdu, Chongqing, Guangzhou, Hangzhou, Jilin City, Nanning, Shenzhen, Xiamen, Zhengzhou
Age
18 years to 65 years
People
200
Run by
Ausper Biopharma Co., Ltd.
See details and how to joinNCT07137910
No phaseTaking people
Follow-up of Chronic Hepatitis B Patients With Comorbid Nonalcoholic Fatty Liver Disease
Where
Hong Kong
People
1,500
Run by
Humanity and Health Research Centre
See details and how to joinNCT02863757